A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

NCT ID: NCT01317901

Last Updated: 2017-06-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-05-31
• Study Completion Date: 2013-06-30

Brief Summary

This was a Phase 1 multicenter study of bendamustine, rituximab and TRU-016 (BRT) in subjects with relapsed indolent B-cell lymphoma. This was a multiple-dose escalation study to determine the maximum-tolerated dose (MTD) of TRU-016 given in combination with rituximab and bendamustine and to determine a safe dosing regimen for the combination in up to 12 subjects with relapsed indolent lymphoma.

The originally planned Phase 2 portion, an open-label, randomized study to evaluate the efficacy of BRT compared with BR, was not conducted.

Detailed Description

This study was planned to be conducted in 2 parts: a Phase 1b component designed to determine a safe dosing regimen, and a Phase 2 component designed to evaluate the efficacy of BRT compared to BR in subjects with relapsed indolent lymphoma. The Phase 2 component was not conducted.

This was an open-label, non randomized, multiple-dose escalation study to determine the MTD of BRT and to determine a safe dosing regimen for the combination in subjects with relapsed indolent lymphoma.

The study consisted of a screening period lasting up to 21 days, a treatment period lasting up to 6 cycles (28 days each), and a 60-day follow-up period. Up to 12 subjects (2 cohorts of 6 subjects each) were planned for enrollment. Two dose levels (10 and 20 mg/kg) of TRU-016 combined with rituximab 375 mg/m2 and bendamustine 90 mg/m2 were evaluated during up to 6 cycles (28 days each). TRU-016 was administered by intravenous (IV) infusion on Days 1 and 15 of each cycle. Rituximab was administered by IV infusion on Day 2 of each cycle. Bendamustine was administered by IV infusion on Days 1 and 2 of each cycle. Subjects received study treatment for up to 6 cycles.

Conditions

B-cell Small Lymphocytic Lymphoma Recurrent

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TRU-016+bendamustine+rituximab

Two dose levels (10 and 20 mg/kg) of TRU 016 combined with rituximab 375 mg/m2 and bendamustine 90 mg/m2 were evaluated during up to 6 cycles (28 days each). TRU-016 was administered by intravenous (IV) infusion on Days 1 and 15 of each cycle. Rituximab was administered by IV infusion on Day 2 of each cycle. Bendamustine was administered by IV infusion on Days 1 and 2 of each cycle. Subjects received study treatment for up to 6 cycles.

Group Type: EXPERIMENTAL

TRU-016

Intervention Type: DRUG

100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle

Bendamustine

Intervention Type: DRUG

Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.

Rituximab

Intervention Type: DRUG

Rituximab by IV administration at 375 mg/m\^2 on Day 2 of each 28 day cycle.

Interventions

TRU-016

100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle

Intervention Type: DRUG

Bendamustine

Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.

Intervention Type: DRUG

Rituximab

Rituximab by IV administration at 375 mg/m\^2 on Day 2 of each 28 day cycle.

Intervention Type: DRUG

Other Intervention Names

otlertuzumab; Treanda; rituxan

Eligibility Criteria

Inclusion Criteria

1. Age 18 years or older

2. Histologically confirmed diagnosis of indolent non-Hodgkin's B-cell lymphoma (ie, follicular lymphoma, small lymphocytic lymphoma, and marginal zone lymphoma) that has relapsed (relapsed is defined as confirmed progressive disease (PD) after receiving the most recent prior therapy, or failure to achieve at least a partial response (PR) while receiving the most recent prior therapy)

3. At least one prior line of therapy for indolent lymphoma

4. Bi-dimensionally measurable disease with at least one lesion measuring >=1.5 cm in a single dimension

5. Eastern Cooperative Oncology Group (ECOG) performance status of <= 2

6. Creatinine clearance of >40 mL/min as calculated by the

Cockcroft-Gault method as follows:

(140 - age) * (weight in kg [* 0.85 if female] / 72 * serum creatinine level) 7. Adequate hepatic function, indicated as follows:

• aspartate aminotransferase (AST) of <2.5 x upper limit of normal (ULN)
• alanine aminotransferase (ALT) of <2.5 x ULN
• total bilirubin of <= 1.5 x ULN 8. Absolute neutrophil count (ANC) >=1000/mm3 (1000/µL) 9. Platelet count >= 100,000/mm3 10. Female subjects of child-bearing potential and male subjects must use an acceptable form of birth control for the duration of their study participation and for 6 months after completing study drug dosing; acceptable forms of birth control, unless dictated otherwise by local regulatory authorities 11. For women of childbearing potential, a negative serum pregnancy test result obtained during the screening period and a negative urine pregnancy test result within 24 hours before first administration of study drug 12. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information

Exclusion Criteria

1. Diagnosis of grade 3b follicular lymphoma or transformed lymphoma of any grade

2. Previously received TRU-016

3. Prior treatment with rituximab if subject discontinued rituximab due to unresolved toxicity

4. Refractory to bendamustine, defined as follows:

• progression within 6 months of last dose of bendamustine
• failed to achieve at least a PR while receiving bendamustine
• discontinued bendamustine due to toxicity
• received bendamustine within 6 months prior to first dose of study drug

5. Received chemotherapy, radiotherapy, or immunotherapy including investigational agents within 28 days prior to the first dose of study drug

6. Received therapeutic corticosteroids at doses equivalent to >10 mg prednisone per day for longer than 5 days within 14 days prior to the first dose of study drug, except if needed as a pre-medication

7. Received filgrastim or equivalent within 14 days prior to screening (ie, collection of samples for laboratory tests) or pegfilgrastim within 28 days prior to screening (ie, collection of samples for laboratory tests)

8. Prior allogeneic bone marrow transplant

9. Prior autologous bone marrow transplant within 12 months prior to the first dose of study drug

10. Received blood or platelet infusion within 7 days prior to screening (ie, collection of samples for laboratory tests)

11. Previous or concurrent additional malignancy except non-invasive, non-melanomatous skin cancer or in situ carcinoma of the cervix, or other solid tumors if the subject has been disease-free for a minimum of 2 years prior to the first dose of study drug

12. Known central nervous system or leptomeningeal lymphoma

13. Any significant concurrent medical diseases or conditions, including but not limited to the following:

• Clinically significant pulmonary dysfunction requiring oxygen therapy
• An active infection (viral, bacterial, or fungal) requiring systemic therapy; subjects receiving prophylactic therapy are eligible

14. Known allergy to mannitol

15. History of positive serology for human immunodeficiency virus (HIV)

16. Positive serology for hepatitis B (surface antigen or core antibody) Note: If a positive test result for hepatitis B core antibody is due to immunoglobulin treatment, the subject may be enrolled if the hepatitis B viral deoxyribonucleic acid (DNA) is negative.

17. Positive serology for hepatitis C

18. Pregnant or breastfeeding

19. Other severe, acute, or chronic medical or psychiatric condition, laboratory abnormality, or difficulty complying with protocol requirements that may increase the risk associated with study participation or study drug administration or may interfere with safety

20. Any condition that, in the investigator's opinion, makes the subject unsuitable for study participation

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aptevo Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Scott Stromatt, MD

Role: STUDY_DIRECTOR

Aptevo Therapeutics

Locations

Site Reference ID/Investigator# 61543

Birmingham, Alabama, United States

Site Reference ID/Investigator# 61542

Augusta, Georgia, United States

Site Reference ID/Investigator# 61523

Omaha, Nebraska, United States

Site Reference ID/Investigator# 61522

Hackensack, New Jersey, United States

Site Reference ID/Investigator# 61544

Chapel Hill, North Carolina, United States

Site Reference ID/Investigator# 61524

Seattle, Washington, United States

Countries

United States

References

Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, Mato AR, Eisenfeld AJ, Stromatt SC, Goy A. Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Invest New Drugs. 2014 Dec;32(6):1213-25. doi: 10.1007/s10637-014-0125-2. Epub 2014 Jun 15.

Reference Type: BACKGROUND

PMID: 24927856 (View on PubMed)

Other Identifiers

16011

Identifier Type: -

Identifier Source: org_study_id